Table 1.
Baseline Patient Characteristics
| All patients | TKI(−) | TKI(+) | P value | |
|---|---|---|---|---|
| No. patients | 22 | 11 | 11 | NS |
| Age (years) | 63.3±13.6 | 63.8±10.1 | 62.8±16.5 | NS |
| Male | 17 (77.3) | 9 (81.8) | 8 (72.7) | NS |
| BMI (kg/m2) | 22.2±4.0 | 22.2±4.5 | 22.3±3.6 | NS |
| Hypertension | 14 (63.6) | 7 (63.6) | 7 (63.6) | NS |
| SBP (mmHg) | 115.4±10.3 | 113.9±11.4 | 116.9±8.9 | NS |
| DBP (mmHg) | 65.6±10.2 | 67.0±10.7 | 64.2±9.6 | NS |
| Diabetes | 3 (13.6) | 3 (27.2) | 0 | NS |
| Current/former smoker | 15 (68.2) | 7 (63.6) | 8 (72.7) | NS |
| Dyslipidemia | 3 (13.6) | 2 (18.2) | 1 (9.1) | NS |
| Serum creatinine (mg/dL) | 1.27±0.3 | 1.01±0.3 | 1.51±0.67 | 0.02 |
| Cardiovascular disease | 4 (18.2) | 2 (18.2) | 2 (18.2) | NS |
| Coronary artery disease | 2 (9.1) | 1 (9.1) | 1 (9.1) | NS |
| Atrial fibrillation | 1 (4.5) | 1 (9.1) | 0 | NS |
| Chronic heart failure | 1 (4.5) | 0 | 1 (9.1) | NS |
| ECOG performance status | ||||
| 0 | 14 (63.6) | 7 (63.6) | 7 (63.6) | NS |
| 1 | 8 (36.4) | 4 (36.4) | 4 (36.4) | NS |
| >1 | 0 | 0 | 0 | NS |
| Histological subtypes | ||||
| Clear cell | 20 (90.9) | 10 (90.9) | 10 (90.9) | NS |
| Papillary | 2 (9.1) | 1 (9.1) | 1 (9.1) | NS |
| Chemotherapy | ||||
| Interferon-α | 2 (9.1) | 2 (18.2) | 0 | NS |
| Everolimus | 6 (27.3) | 6 (54.5) | 0 | 0.006 |
| Sorafenib | 1 (4.5) | 0 | 1 (9.1) | NS |
| Sunitinib | 9 (40.9) | 0 | 9 (81.8) | 0.002 |
| Pazopanib | 1 (4.5) | 0 | 1 (9.1) | NS |
| Nivolumab | 3 (13.6) | 3 (27.2) | 0 | NS |
| Antihypertensive drugs | ||||
| ACEI/ARB | 5 (22.7) | 3 (27.2) | 2 (18.2) | NS |
| Ca2+ channel blocker | 7 (31.8) | 2 (18.2) | 5 (45.4) | NS |
| β-blocker | 5 (22.7) | 3 (27.2) | 2 (18.2) | NS |
| Diuretics | 5 (22.7) | 3 (27.2) | 2 (18.2) | NS |
Unless indicated otherwise, data are presented as the mean±SD or as n (%). ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; DBP, diastolic blood pressure; ECOG, Eastern Cooperative Oncology Group; SBP, systolic blood pressure; TKI, tyrosine kinase inhibitor.